A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD.

@article{Feldman2016ARB,
  title={A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD.},
  author={Gregory J. Feldman and François Maltais and Sanjeev Khindri and Mitra Vahdati-Bolouri and Alison M. Church and William A. Fahy and Roopa Trivedi},
  journal={International journal of chronic obstructive pulmonary disease},
  year={2016},
  volume={11},
  pages={719-30}
}
BACKGROUND The long-acting muscarinic antagonists umeclidinium (UMEC) and tiotropium (TIO) are approved once-daily maintenance therapies for COPD. This study investigated the efficacy and safety of UMEC versus TIO in COPD. METHODS This was a 12-week, multicenter, randomized, blinded, double-dummy, parallel-group, non-inferiority study. Patients were… CONTINUE READING